Cerebrospinal fluid biomarkers of Alzheimer's disease in Lewy body diseases: The performance of fully automated immunoassays
Journal of Alzheimer’s Disease · 2025
DOI: 10.1177/13872877251360404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2025. Verfasst von Joyce Ruifen Chong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Healthy Brain Aging, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Lo…. Hauptthemen laut MEDLINE: Lewy Body Disease, Alzheimer Disease, Amyloid beta-Peptides, tau Proteins. Die Arbeit nennt 49 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
The potential role of Alzheimer's disease (AD) pathology in contributing to cognitive impairment in α-synucleinopathies warrants in vivo detection of the pathological burden in patients with α-synucleinopathies.
Objective
Using a fully automated platform, we measured the levels of cerebrospinal fluid (CSF) AD biomarkers, namely Aβ 42 , P-tau181 and T-tau, as well as their derived ratios, P-tau181/Aβ 42 ratio and T-tau/Aβ 42 ratio, in a cohort of Parkinson's disease (PD), dementia with Lewy bodies (DLB), preclinical and prodromal AD (pAD) patients, as well as cognitively normal controls. We binarized the CSF biomarkers and determined the proportion of individuals with abnormal biomarker levels within each diagnostic group. We explored the associations between these biomarkers and cognitive performance.
Methods
This study consisted of 51 controls, 46 PD, 65 DLB, and 50 pAD patients. CSF biomarkers were measured using Roche Elecsys ® immunoassays. Cognitive performance was based on Mini-Mental State Examination (MMSE).
Results
CSF P-tau181/Aβ 42 and T-tau/Aβ 42 ratios were increased in DLB and pAD, but not PD, compared with controls. Both DLB and pAD had higher proportions of individuals with abnormal CSF P-tau181/Aβ 42 ratio (AD = 100%, DLB = 59%, PD = 37% and controls = 26%) and T-tau/Aβ 42 ratio (AD = 100%, DLB = 51%, PD = 26% and controls = 18%). Within each diagnostic group, there was no association between CSF AD biomarkers and cognition.
Conclusions
CSF AD biomarkers profile is prevalent in DLB. Our findings highlight the potential utility of Elecsys ® immunoassay platform for the evaluation of AD pathology in α-synucleinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Healthy Brain Aging, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- Department of Pharmacology, National University of Singapore, Singapore, Singapore.
- Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
ORCID-Profile: Joyce Ruifen Chong, Mercè Boada, Per Svenningsson
Zitieren
APA
Chong, J. R., Hye, A., Boada, M., Svenningsson, P., Fladby, T., & Aarsland, D. (2025). Cerebrospinal fluid biomarkers of Alzheimer's disease in Lewy body diseases: The performance of fully automated immunoassays. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877251360404
Vancouver
Chong JR, Hye A, Boada M, Svenningsson P, Fladby T, Aarsland D. Cerebrospinal fluid biomarkers of Alzheimer's disease in Lewy body diseases: The performance of fully automated immunoassays. Journal of Alzheimer’s Disease. 2025. doi:10.1177/13872877251360404
BibTeX
@article{Chong2025,
author = {Chong, Joyce Ruifen and Hye, Abdul and Boada, Mercè and Svenningsson, Per and Fladby, Tormod and Aarsland, Dag},
title = {Cerebrospinal fluid biomarkers of Alzheimer's disease in Lewy body diseases: The performance of fully automated immunoassays},
journal = {Journal of Alzheimer’s Disease},
year = {2025},
doi = {10.1177/13872877251360404}
}
EUVIMED